Abstract: A method for extracting carboxylic acids from an aqueous fermentation broth is disclosed. The method involves first contacting the broth with carbon dioxide under pressure to acidify the mixture. The acidified broth is then contacted with a liquid extractant, such as an amine, to form a carboxylic acid-base complex, which extracts the acid from the aqueous phase. The carboxylic acid is subsequently recovered by breaking this complex. In some embodiments, a strong base is used to break the complex, yielding a salt of the carboxylic acid. In other embodiments, heat or gas stripping is applied to release the free carboxylic acid and regenerate the extractant for recycling. The process may be enhanced by using membrane-based liquid-liquid contactors.

Abstract: A biomass processing system is disclosed whereby a counter flow path is provided for recovering yielded product from at least two fermentation stages. In certain configurations, the counter flow path is associated with respective extraction stages that correspond to each respective fermentation stages. To enhance product recovery, certain configurations also disclose mechanical grinding of biomass between fermentation stage to enhance a surface area for further subsequent processing of the biomass. To yet further enhance the system, certain configurations discloses a cell recovery sub-system that agitates processed biomass to separate cells from undigested residues. The recovered cells may be recycled to fermentation stages in the system.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A biomass processing system is disclosed whereby a counter flow path is provided for recovering yielded product from at least two fermentation stages. In certain configurations, the counter flow path is associated with respective extraction stages that correspond to each respective fermentation stages. To enhance product recovery, certain configurations also disclose mechanical grinding of biomass between fermentation stage to enhance a surface area for further subsequent processing of the biomass. To yet further enhance the system, certain configurations discloses a cell recovery sub-system that agitates processed biomass to separate cells from undigested residues. The recovered cells may be recycled to fermentation stages in the system.

Abstract: A cap, a method of using a cap, and a system for using the cap. The cap is capable of being fitted to a bottle. The cap includes a transfer port; and a vent port. The vent port includes a membrane and a valve.

Abstract: A cap, a method of using a cap, and a system for using the cap. The cap is capable of being fitted to a bottle. The cap includes a transfer port; and a vent port. The vent port includes a membrane and a valve.